Status:
UNKNOWN
The Occurrence of MACE in Patients With AMI Receiving Pitavastatin/Valsartan Treatment
Lead Sponsor:
JW Pharmaceutical
Conditions:
Hypercholesterolemia
Eligibility:
All Genders
19+ years
Brief Summary
Prospective Observation study to identify the rate of MACE in AMI with Livalo V(Pitavastatin/Valsartan) for 12 month in Korea
Detailed Description
Following subjects with AMI event within 1 month will be assessed MACE event for 1year * Essential hypertension or heart failure * Idiopathic hypercholesterolemia (heterogeneous familial and non-fami...
Eligibility Criteria
Inclusion
- idiopathic hypercholesterolemia (heterogeneous familial and non-familial, Fredrickson type IIa) or mixed-type (Fredrickson type IIb) with AMI (STEMI, NSTEMI), including essential hypertension or heart failure
- diagnosed AMI (STEMI, NSTEMI) 1 months ago
- more than 19 years old and more than 2 years of life expectancy at screening
- informed consent
Exclusion
- cardiogenic shock or corresponding clinical events
- contraindicated to the IP
- unsuitable to this study judged by investigators
Key Trial Info
Start Date :
July 1 2018
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
June 30 2022
Estimated Enrollment :
905 Patients enrolled
Trial Details
Trial ID
NCT04270344
Start Date
July 1 2018
End Date
June 30 2022
Last Update
April 13 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
JWP
Seoul, Seocho-gu, South Korea